胸部肿瘤放疗致心脏损伤的磁共振成像和核医学研究进展  

Research progress of magnetic resonance imaging and nuclear medicine on heart disease induced by radiotherapy of thoracic tumors

作　　者：王茸 谢萍 王海军[1] WANG Rong;XIE Ping;WANG Haijun(Department of Nuclear Medicine,Gansu Provincial Hospital,Lanzhou 730000,China;The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Department of Cardiology,Gansu Provincial Hospital,Lanzhou 730000,China)

机构地区：[1]甘肃省人民医院核医学科,兰州730000 [2]兰州大学第一临床医学院,兰州730000 [3]甘肃省人民医院心内科,兰州730000

出　　处：《磁共振成像》2022年第12期146-149,共4页Chinese Journal of Magnetic Resonance Imaging

基　　金：国家自然科学基金(编号:81860047);甘肃省自然科学基金(编号:21JR1RA025)。

摘　　要：放射性心脏损伤(radiation induced heart disease,RIHD)是一种异质性和复杂的疾病,通常情况下临床表现隐匿,并与多种疾病重叠,缺乏特异性。准确识别亚临床心脏受累和早期干预可使胸部肿瘤患者放疗效益最大化,提高预后。心脏磁共振(cardiac magnetic resonance,CMR)和核医学在检测RIHD患者亚临床心脏受累方面具有优势,为RIHD患者的治疗和预后评估提供指导。本文就CMR和核素心肌显像在胸部肿瘤RIHD亚临床诊断及定量评估等方面的应用及研究进展进行综述。Radiation-induced heart disease(RIHD)is a heterogeneous and complex disease,usually with insidious clinical manifestations,overlapping with multiple diseases,and lack of specificity.Accurate identification of subclinical cardiac involvement and early intervention maximizes the benefit of radiotherapy and improves the prognosis of patients with thoracic tumors.Cardiac magnetic resonance(CMR)and nuclear medicine have advantages in detecting subclinical cardiac involvement in patients with RIHD,and providing guidance for the treatment and prognosis assessment of patients with RIHD.This article reviews the application and research progress of CMR and radionuclide myocardial imaging in the subclinical diagnosis and quantitative assessment of RIHD patients with thoracic tumor.

关 键 词：胸部肿瘤 放疗 心脏损伤 磁共振成像 核医学 早期诊断 

分 类 号：R445.2[医药卫生—影像医学与核医学] R818.74[医药卫生—诊断学]